GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adlai Nortye Ltd (NAS:ANL) » Definitions » Debt-to-EBITDA

Adlai Nortye (Adlai Nortye) Debt-to-EBITDA : -0.09 (As of Jun. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Adlai Nortye Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Adlai Nortye's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $20.50 Mil. Adlai Nortye's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $0.66 Mil. Adlai Nortye's annualized EBITDA for the quarter that ended in Jun. 2023 was $-250.32 Mil. Adlai Nortye's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2023 was -0.08.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Adlai Nortye's Debt-to-EBITDA or its related term are showing as below:

ANL' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.41   Med: -0.25   Max: -0.12
Current: -0.41

During the past 3 years, the highest Debt-to-EBITDA Ratio of Adlai Nortye was -0.12. The lowest was -0.41. And the median was -0.25.

ANL's Debt-to-EBITDA is ranked worse than
100% of 276 companies
in the Biotechnology industry
Industry Median: 1.31 vs ANL: -0.41

Adlai Nortye Debt-to-EBITDA Historical Data

The historical data trend for Adlai Nortye's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adlai Nortye Debt-to-EBITDA Chart

Adlai Nortye Annual Data
Trend Dec21 Dec22 Dec23
Debt-to-EBITDA
-0.25 -0.12 -0.31

Adlai Nortye Quarterly Data
Dec21 Mar22 Jun22 Dec22 Mar23 Jun23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial - N/A -0.21 -0.09 N/A

Competitive Comparison of Adlai Nortye's Debt-to-EBITDA

For the Biotechnology subindustry, Adlai Nortye's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adlai Nortye's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adlai Nortye's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Adlai Nortye's Debt-to-EBITDA falls into.



Adlai Nortye Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Adlai Nortye's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(31.079 + 0.469) / -101.215
=-0.31

Adlai Nortye's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(20.496 + 0.664) / -250.324
=-0.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2023) EBITDA data.


Adlai Nortye  (NAS:ANL) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Adlai Nortye Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Adlai Nortye's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Adlai Nortye (Adlai Nortye) Business Description

Traded in Other Exchanges
Address
685 US Highway 1, North Brunswick, NJ, USA, 08902
Adlai Nortye Ltd is a global clinical-stage biotechnology company focused on the discovery and development of innovative cancer therapies for patients across the spectrum of tumor types. The company has robust pipeline of drug candidates it includes buparlisib (AN2025), palupiprant (AN0025), and AN4005, as well as four preclinical candidates.

Adlai Nortye (Adlai Nortye) Headlines